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We hypothesised that gastric cancer outcome could be improved with more effective and intensified postoperative
chemoradiotherapy. This phase I/II study was performed to determine the maximal tolerated dose (MTD) and toxicity profile of
postoperative radiotherapy with concurrent daily cisplatin and capecitabine. Patients were treated with capecitabine 1000mgm
 2
twice a day (b.i.d.) for 2 weeks. Subsequently, patients received capecitabine (250–650mgm
 2 orally b.i.d., 5daysweek
 1) and
cisplatin (3–6mgm
 2 i.v., 5daysweek
 1) according to an alternating dose-escalation schedule. Radiotherapy was given to a total
dose of 45Gy in 25fractions. Thirty-one patients completed treatment. During chemoradiotherapy, eight patients developed nine
items of grade III and one episode of grade IV (mainly haematological) toxicity. The MTD was determined to be cisplatin 5mgm
 2 i.v.
and capecitabine 650mgm
 2 b.i.d. orally. This phase I/II study demonstrated that chemoradiotherapy with daily cisplatin and
capecitabine is feasible in postoperative gastric cancer at the defined dose level and is currently being tested in a phase III multicenter
study.
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Surgical resection remains the cornerstone of curative treatment
of gastric cancer (Jansen et al, 2005). However, with surgery
only, long-term survival is poor, especially in patients with
T3–4 tumours and/or tumour-positive lymph nodes (Wanebo
et al, 1993; Hundahl et al, 2000). This could be, at least in part,
accounted for by locoregional relapses that are reported up to
82% (Gunderson and Sosin, 1982). Randomised studies that
compared standard D1 lymph node dissections with more
extended D2 resections in the Western world, failed to show a
significant survival benefit with more extensive surgery (Cuschieri
et al, 1999; Hartgrink et al, 2004). Many studies have been
performed to test whether postoperative chemotherapy improves
survival. These studies are part of several meta-analyses, which at
the best show only a modest survival benefit (Hermans et al, 1993;
Earle and Maroun, 1999; Mari et al, 2000; Gianni et al, 2001;
Janunger et al, 2002). Recently, a substantial increase in survival
was found with perioperative chemotherapy in the MAGIC
study (Cunningham et al, 2006a,b). In this randomised phase III
study of 503 patients, three courses of epirubicin, cisplatin and
5-FU (ECF) chemotherapy before surgery and three courses
afterwards significantly prolonged progression-free and overall
survival (23% for surgery only and 36% with perioperative
chemotherapy at 5 years). Earlier, in a trial from the British
Stomach Cancer group, no advantage of postoperative radio-
therapy only was found (Allum et al, 1989). Another strategy
to improve survival is postoperative chemoradiotherapy. The
Intergroup 0116 study showed in a randomised study of 556
patients that postoperative chemoradiotherapy with 5-FU pro-
longed 5-year overall survival to 40% as compared to 22% with
surgery only (Macdonald et al, 2001). This study has been
criticised for the fact that 54% of the patients that were included
had undergone a D0 lymph node dissection, what can be regarded
as suboptimal (Hundahl et al, 2002). In this study, which was
initiated in the beginning of the 90s of the previous century,
chemotherapy was given concurrently only during the first 4 and
last 3 days – to a total of 7 days – of radiotherapy, resulting in only
a limited interaction between both treatment modalities. We
hypothesised that more intensive concurrent treatment with daily
cisplatin and capecitabine (which mimics continuous 5-FU
infusion) would be more effective (Hoff et al, 2001; Evans et al,
2002). Therefore, we developed a phase I/II study where
conventionally fractionated radiotherapy (45Gy in 25fractions,
equal to the Intergroup study) was combined with daily oral
capecitabine. Cisplatin was added to this regime because of its
radiosensitising properties in other malignancies (Schaake-Koning
et al, 1992; al Sarraf et al, 1997; Rose et al, 1999; Bernier et al,
2004). Both chemotherapeutic drugs were escalated in an
alternating fashion.
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sMATERIALS AND METHODS
Patients
Patients with histologically proven adenocarcinoma of stomach or
gastro-oesophageal junction in AJCC stage Ib-IV (M0) were
eligible for this study (Greene, 2002). Patients with previous
malignancies or comorbidity that might compromise delivery of
the planned treatment were excluded. Treatment had to be started
within 75 days after surgery.
All patients were asked to participate in this study after
macroscopically radical gastric surgery was performed. Patients
had to be 418 years old, with a WHO performance status
of p2. Haematology: haemoglobin X6.5mmoll
 1; leucocytes
X3.5 10
9l
 1; neutrophils X1.5 10
9l
 1 and thrombocytes
X100 10
9l
 1. Renal function: serum creatinine p1.25 ULN
and creatinine clearance X60mlmin
 1 as assessed by 24h urine
collection or calculated by Cockroft and Gault formula. Liver
function: total bilirubin p1.5 ULN; alkaline phosphatase and
ASAT/ALAT p3 ULN. Before treatment, a baseline Tc
99m-
thiatide renogram was performed to evaluate the relative function
of the left and right kidney. All patients underwent physical
examination, chest X-ray, chest and abdominal CT scans, ECG and
evaluation of caloric intake by a dietitian at baseline. A caloric
intake of at least 1500kcalday
 1 had to be established. During
treatment, patients had weekly physical examination, testing of
haematological, liver and renal function and determination of
weight, caloric intake and toxicity (NCI CTC v3.0). Furthermore,
the pathological specimens were reviewed at the Netherlands
Cancer Institute.
The study was approved by the Medical Ethical Committee of
the Netherlands Cancer Institute, and all patients gave written
informed consent.
Treatment design
The objectives of this phase I/II study were to find the maximal
tolerable dose (MTD) of two chemotherapeutic agents, cisplatin
and capecitabine, with a fixed radiotherapeutic regimen of 45Gy
and to develop a treatment schedule that could be the experimental
arm in a subsequent phase III study. Doses of cisplatin and
capecitabine were escalated alternately in dose levels consisting of
three patients each. Dose-limiting toxicity (DLT) was defined as
any Xgrade 3 event at any time up to 4 weeks after treatment,
except for neutropaenia which was defined as dose-limiting only
when being grade IV, with neutropaenic fever, with neutropaenic
infection or when it occurred in the first 14 days (capecitabine
only) of treatment. When DLT was encountered, an extra group of
three patients was treated in the same dose level.
All patients underwent a (partial or total) gastrectomy with
preferably at least a D1 lymph node dissection. No routine
splenectomy or pancreatic tail resection was done. Whenever
possible, jejunostomies were left in situ for the entire postsurgical
treatment period to facilitate adequate caloric intake.
Because of logistic reasons (waiting time for radiotherapy), all
patients started with 2 weeks (days 1–14) of monotherapy with
capecitabine 1000mgm
 2 twice a day (b.i.d.), after which a non-
treatment week (day 15–21) followed. On day 22, radiotherapy
started which consisted of 25fractions of 1.8Gy to a total dose of
45Gy in 5 weeks (5fractionsweek
 1). On radiotherapy days,
cisplatin (3–6mgm
 2 i.v. once daily 1h before radiotherapy) and
capecitabine (250–650mgm
 2 orally b.i.d., first dose prior to
radiotherapy) were given.
The clinical target volume for radiotherapy consisted of the
gastric bed (with stomach remnant when present), anastomoses
and the draining lymph nodes, as was described in the Intergroup
0116 study (Macdonald et al, 2001). Until the end of 2003, two-field
AP-PA techniques (12 patients) were used in treatment, since then
multiple field (three-dimensional conformation techniques and/or
Intensity Modulated RT (IMRT) techniques (20 patients) were
used.
All patients had CT-based dose calculation with construction of
dose volume histograms. Dose constraints for critical organs were
mean liver dose o30Gy and for kidneys, at least two-third of one
kidney should receive a dose of o40% of the total dose. All
patients were treated in a supine position without immobilisation
measures on Linacs. Patients were weekly seen by their radiation
oncologist and gastrointestinal oncologist. Twice weekly haema-
tology and serum creatinine were checked. All patients were also
strictly monitored by a dietitian. Anti-emetics were given on a
prophylactic basis, antacid and anti-diarrheic drugs were pre-
scribed when needed.
RESULTS
Between December 2002 and March 2006 35 patients were entered
in this study. Three patients went off study in an early phase of
treatment: one because of a cisplatin allergy with skin reaction
which was confirmed after rechallenge; one because of patient
refusal to take oral capecitabine and one patient had received para-
aortic node irradiation because of bladder cancer in another
hospital 20 years before that precluded adequate gastric radio-
therapy. Thus, 32 patients started treatment and could be
evaluated for acute toxicity. Patient characteristics are summarised
in Table 1.
All patients finished the 2 weeks of capecitabine only. One
patient developed grade III hand-foot syndrome, which was
considered to be not dose-limiting, because it initiated at the
capecitabine only phase of treatment and the purpose of this study
was to evaluate toxicity of chemoradiotherapy. All but one patient
completed the chemoradiotherapy part of treatment. A 68-year-old
woman deteriorated during the first week of chemoradiotherapy
Table 1 Patient characteristics (n¼32)
Sex (M/F) 22/10
Mean age (range; years) 53 (37–73)
Histology
Adenocarcinoma 30
Signet cell carcinoma 2
Location of primary tumour
Gastro-oesophageal 5
Stomach 27
Surgery
Partial gastrectomy 15
Oesophagogastrectomy 6
Total gastrectomy 11
Lymph node dissection
D0 13
D1 13
D2 6
pT-stage
T1 1
T2 3
T3 24
T4 4
pN-stage
N0 3
N1 15
N2 10
N3 4
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streatment and was admitted on the intensive care unit with
neutropaenic fever and severe mucositis of small bowel leading to
bacterial translocation, sepsis and ultimately pulmonary failure.
This patient was treated in the highest dose level (cisplatin
6mgm
 2; capecitabine 650mgm
 2 b.i.d.) and although this
patient did not finish treatment according to the protocol, the
toxicity was considered dose-limiting. Although a dihydropyrimi-
dine dehydrogenase (DPD) deficiency was suspected, DPD enzyme
activity measured in peripheral blood mononuclear cells was not
decreased. The patient fully recovered with no signs of disease. In
five patients, a dose reduction (of capecitabine) was applied
because of neutropaenia (2), chest pain (1); hand-foot syndrome
(1) and DPD deficiency (1). Grade III/IV toxicity of the remaining
31 patients is summarised in Table 2. Eight patients developed
nine items of grade III toxicity, one patient developed grade I
toxicity. There was no toxicity related mortality. DLTs were grade
III and IV neutropaenia, grade III thrombocytopaenia and grade
III nausea. The MTD therefore was cisplatin 5mgm
 2 i.v. and
capecitabine 650mgm
 2 b.i.d. orally. To get a better view on the
spectrum of toxicity at this dose level, two extra patients to a total
of 8 were treated in this dose level.
At time of analysis after a median follow-up of 14.4 (4.8–41.7)
months, 20 patients are alive and 11 have died. A Kaplan–Meier
plot of overall survival is depicted in Figure 1. One patient died due
to local recurrence, seven due to distant metastases and three due
to synchronous distant metastases and local recurrence. No patient
died due to treatment-related toxicity.
DISCUSSION
When the Intergroup 0116 trial was initiated at the beginning of
the 90s, the concept of concurrent chemoradiotherapy was not as
widespread as it is nowadays. Especially, cisplatin-based chemor-
adiotherapy with daily or weekly administration has proven to be
effective in a wide range of malignancies like head and neck, lung
and uterine cervix cancer (Schaake-Koning et al, 1992; Rose et al,
1999; Bernier et al, 2004). Furthermore, daily administration of
5-FU analogues has become much easier with the introduction of
the oral fluoropyrimidines such as capecitabine. In metastatic colo-
rectal cancer, capecitabine has shown to be at least as effective and
to have a favourable side effect profile when compared with
intravenous 5-FU (Hoff et al, 2001; Cunningham et al, 2006b).
Capecitabine concurrent with radiotherapy has shown to be
feasible and capable of inducing relevant tumour responses in
upper GI and rectal cancer (Vaishampayan et al, 2002; Rodel et al,
2003).
We therefore designed this phase I/II study where a fixed
radiotherapy regimen comparable to the Intergroup 0116 trial,
was combined with daily cisplatin and capecitabine during
weekdays. Capecitabine has been used in gastric cancer in the
epirubicin/cisplatin/capecitabine (ECC) regimen with adequate
resorption in patients with or without gastric resection (Evans
et al, 2002).
We demonstrated that postoperative chemoradiotherapy with
daily cisplatin and capecitabine during weekdays combined with
45Gy radiotherapy in 25 fractions is feasible (after 2 weeks of
capecitabine monotherapy). The recommended dose for further
studies are for cisplatin 5mgm
 2 i.v. daily and for capecitabine
650mgm
 2 b.i.d. orally. Ninety-seven percent of patients com-
pleted the planned treatment. Although we want to emphasise that
comparison of our phase I/II toxicity data with large phase III
studies is not appropriate, it is stressed that this is in clear contrast
to the 64% of patients receiving planned treatment in the
Intergroup 0116 trial and 42% of patients in the MAGIC trial. It
may reflect the fact that (i) our initial doses of chemotherapy were
relatively low, (ii) more conformal radiotherapy techniques were
used, (iii) these large phase III trials were multicentre trials and
ours is a single institution trial with strict monitoring of the
patients, and (iv) underscores the importance of intense suppor-
tive care (Macdonald et al, 2001; Cunningham et al, 2006a).
Furthermore, in the MAGIC protocol, chemotherapy was also
applied preoperatively, which could diminish tolerability of
postoperative treatments. In the Intergroup 0116 study 54% of
chemoradiotherapy patients developed Xgrade III haematological
toxicity and in 33% gastrointestinal toxicity, ultimately resulting in
17% of patients withdrawing from the protocol. In the MAGIC
study Xgrade III haematological toxicity consisted mainly of
granulocytopaenia (24–28%), lymphocytopaenia (17–20%) and
leucopaenia (11–12%). Gastrointestinal toxicity was somewhat
lower with about 16% Xgrade III nausea and 14% vomiting.
In the radiotherapy part of treatment only modifications in
clinical target volume delineation have been introduced. In the
beginning of the study, two field AP-PA (anterior-posterior)
techniques were used like in the Intergroup 0116 study, whereas in
the latter part this was replaced by more sophisticated three-
Table 2 Grade III/IV toxicity in relation to chemotherapy dose level during chemoradiotherapy in 31 patients that completed treatment as planned
Dose level
Cisplatin
dose (mgm
 2)
Capecitabine
dose (mgm
 2) n Neutropaenia Thrombocytopaenia Nausea
Hand-foot
syndrome Dysphagia Fatigue
I 3 250 3
II 4 250 3
III 4 350 3
IV 4 500 3 1 1
V 5 575 6 1
a 1
VI 5 650 8 1 1
VII 6 650 5 2 1 1
aGrade IV.
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Figure 1 Kaplan–Meier curve of overall survival of all patients that
entered the trial.
Chemoradiotherapy in gastric cancer
EPM Jansen et al
714
British Journal of Cancer (2007) 97(6), 712–716 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sdimensional conformal and IMRT techniques. In a dose planning
study, we were able to decrease the dose to the (left) kidney while
adequately covering the planning target volume (Verheij et al,
2005; Jansen et al, 2007).
Currently, it is not clear what the optimal strategy to pursue is.
Although both the Intergroup 0116 and the MAGIC study have
contributed in improving the results of gastric cancer treatment,
many questions remain about the optimal treatment. As men-
tioned before, the Intergroup 0116 study has been criticised for its
suboptimal surgery, suggesting that chemoradiotherapy was only
balancing this. However, in an observational study from South
Korea in nearly 1000 patients who all had a D2 lymph node
dissection, it was shown that postoperative chemoradiotherapy
could prolong survival and decrease the recurrence rate (Kim et al,
2005). Especially questions about the optimal type and sequencing
of chemotherapy and the implementation of new radiotherapy and
surgical techniques remain. Therefore, we have designed a
multicentre phase III study, of which accrual already has begun,
in which all patients receive three preoperative courses of ECC,
then have gastric surgery followed by another three courses of
ECC or chemoradiotherapy (http://www.clinicaltrials.gov/ct/show/
NCT00407186). In the experimental arm (chemoradiotherapy)
cisplatin and capecitabine dosages will be used that were defined in
this phase I/II study. Furthermore, surgery requires at least a D1
resection with at least 15 lymph nodes removed in this study.
Above that, quality assurance of surgery (Maruyama index) and
radiotherapy will be part of this study.
In conclusion, the combination of modern radiotherapy with
daily cisplatin and capecitabine is safe with manageable toxicity in
patients who have had curative gastric surgery.
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